Outsmarting a mastermind.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The Notch signaling pathway is crucial for cell development and differentiation.
• Aberrant Notch signaling is implicated in the pathogenesis of various cancers, including T cell acute lymphoblastic leukemia (TALL).
• Targeting protein-protein interactions (PPIs) is a promising therapeutic strategy for diseases driven by aberrant signaling.

Purpose of the Study:

• To investigate the potential of a novel cell-permeable synthetic peptide as a dominant-negative inhibitor of the Notch coactivator Mastermind.
• To evaluate the efficacy of this peptide in blocking oncogenic Notch signaling in TALL models.

Main Methods:

• Design and synthesis of a cell-permeable, stapled peptide mimicking the Notch coactivator Mastermind.
• In vitro and in vivo assays to assess the peptide's inhibitory activity on Notch signaling.
• Evaluation of the peptide's therapeutic effect in TALL models.

Main Results:

• The stapled peptide demonstrated potent dominant-negative inhibitory activity against oncogenic Notch signaling.
• The peptide effectively suppressed tumor growth in TALL models.
• The findings highlight the therapeutic potential of targeting Mastermind-Notch interactions.

Conclusions:

• A novel stapled peptide effectively inhibits oncogenic Notch signaling by targeting the Mastermind coactivator.
• This peptide represents a promising new class of therapeutics for TALL and potentially other diseases driven by PPIs.
• The study validates the strategy of using stapled peptides to disrupt disease-associated PPIs.